Preclinical oncology biotech Nkarta sets terms for $150 million IPO - (NASDAQ via NewsPoints Desk)

  • Nkarta plans to raise up to $150 million in its initial public offering, as reported in NASDAQ.

  • The company, which develops off-the-shelf cancer therapies based on natural killer cells, plans to offer 10 million shares at a price range of $14 to $16.

To read more NewsPoints articles, click here.